clarithromycin has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caumes, E; de Masson, A; Maillart, E; Meyssonnier, V; Papeix, C; Veziris, N | 1 |
1 other study(ies) available for clarithromycin and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Cavitary pulmonary disease in a patient treated with natalizumab.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Clarithromycin; Ethambutol; Female; Humans; Multiple Sclerosis, Relapsing-Remitting; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Natalizumab; Pneumonia, Bacterial | 2014 |